Fourteen Hydroxycut dietary supplement products are being recalled. This product is sold in grocery stores and pharmacies and advertises that it is made from natural ingredients. It is very popular with body builders and dieters. About two dozens reports of liver problems have been reported after using this product. The food and Drug Administration urges users to stop using it immediately.
Other recalls include:Caraco Brand of Digoxin Tablets and Raptiva.
The generic drug maker Caraco Pharmaceutical Laboratories Ltd. has
recalled several of its Caraco brand of digoxin tablets. The tablets
are being recalled because they may differ in size and could have more
or less of the active ingredient, digoxin, than stated on the label.
Digoxin is a drug used to treat heart failure and abnormal heart
The recalled products are 0.125 mg and 0.25 mg of
Caraco Digoxin Tablets, USP, distributed before March 31, 2009, which
are not expired but within the expiration date of September 2011.
events: Tablets with a higher dose of the drug than printed on the
label may be toxic to people who take the product and who have kidney
failure. Taking too much of the drug can cause nausea, vomiting,
dizziness, low blood pressure, abnormal heartbeat, and even death.
Tablets with a lower dose of the drug than printed on the label may not
be effective and could cause abnormal heartbeat. People at risk: Anyone
who has taken the recalled Caraco brand of digoxin tablets.You can
identify the recalled products by appearance:
Digoxin, USP, 0.125 mg is a yellow round-shaped tablet with a cut mark
(score) in the middle on one side and the imprinted number "437" on the
- Caraco Digoxin,
USP, 0.25 mg is a white round-shaped tablet scored in the middle on one
side and imprinted with "441" on the other side.
taking the recalled product and return it to your pharmacy or place of
purchase. Contact your health care professional if you have questions.
Raptiva Being Withdrawn From Market
April 8, 2009, Genentech Inc., the manufacturer of the psoriasis drug
Raptiva (efalizumab), announced that it has begun a voluntary, phased
withdrawal of the product from the U.S. market. The company is taking
this action because of the possible risk of developing progressive
multifocal leukoencephalopathy (PML), a rare but serious brain
infection. By June 8, 2009, Raptiva will no longer be available in the
Raptiva was approved by FDA for the treatment of moderate to severe plaque psoriasis.
events: PML leads to a gradual worsening in the way the nervous system
works, which cannot be reversed, and death. People at risk: People who
have taken Raptiva and have severely weakened immune systems are most
at risk. Longer, continuous use may further increase the risk.